The aims of this study were to describe the steady-state PK profile of osimertinib using non-linear mixed effects modelling (population approach), then to investigate the exposure–response relationship for toxicity and efficacy in unselected patients with advanced EGFR T790M-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.